MedTrace Logo

QuantaFlo HD Clinical Validation Study

NCT07219693 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-10-23

No results posted yet for this study

Summary

The primary aim of this validation protocol is to assess cardiovascular function through transthoracic echocardiography ("Echo") measurements and the QuantaFlo HD test measuring blood flow at the finger during a forced expiration ("FE"). The study examines whether Echo-measured GLS values greater than -16% correlate with abnormal responses during FE as measured by QuantaFlo HD.

Conditions

  • To Assess Cardiovascular Function

Interventions

DEVICE

QuantaFlo HD

blood flow at the finger during a forced expiration

Sponsors & Collaborators

  • Semler Scientific

    lead INDUSTRY

Eligibility

Min Age
22 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-21
Primary Completion
2026-03-31
Completion
2026-06-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07219693 on ClinicalTrials.gov